Announcements Trials
Browse Landscape

Phase

Phase NA 6Phase EARLY_PHASE1 4Phase 3 3Phase 1 3Phase 2 2Phase 4 1Phase 2/3 1Phase 1/2 1

Status

Recruiting 3Completed 2Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 20Carcinoma, Hepatocellular 8Stomach Neoplasms 6Multiple Myeloma 6Colorectal Neoplasms 6Uterine Cervical Neoplasms 4Endometrial Neoplasms 4Small Cell Lung Carcinoma 3Recurrence 3Prostatic Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Melanoma 3Febrile Neutropenia 3Waldenstrom Macroglobulinemia 2Venous Thromboembolism 2Skin Neoplasms 2Pancreatic Neoplasms 2Pancreatic Cancer Non-resectable 2Obesity 2Neoplasm Metastasis 2Lymphoma, B-Cell 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hepatitis B 2Hematologic Neoplasms 2Gastric / Gastroesophageal Junction Adenocarcinoma 2Carcinoma, Non-Small-Cell Lung 2Biliary Tract Neoplasms 2Anemia 2

Interventions

telitacicept 1Pyridostigmine Bromide 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Not yet recruiting × Myasthenia Gravis × Clear all
NCT06723548 2024-12-09

Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis

First Affiliated Hospital of Wenzhou Medical University

Phase 4 Not yet recruiting
30 enrolled

Autoimmune Diseases, Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡